Market open

Innoviva/$INVA

14:30

22:10

05:45

13:25

21:00

1D1W1MYTD1Y5YMAX

About Innoviva

Innoviva Inc is a company with a portfolio of royalties and innovative healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.

Ticker

$INVA

Sector

Health Care

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

Burlingame, United States

Employees

112

Website

www.inva.com

Innoviva Metrics

BasicAdvanced

$1.1B

17.93 $0.99

0.57 -

Price and volume

Market cap

$1.1B

Beta

0.57

52-week high

$20.14

52-week low

$14.33

Average daily volume

609K

Financial strength

Current ratio

12.556

Quick ratio

11.022

Long term debt to equity

77.671

Total debt to equity

77.671

Interest coverage (TTM)

8.56%

Management effectiveness

Return on assets (TTM)

10.36%

Return on equity (TTM)

9.97%

Valuation

Price to earnings (TTM)

17.926

Price to revenue (TTM)

3.157

Price to book

1.66

Price to tangible book (TTM)

2.52

Price to free cash flow (TTM)

6.874

Growth

Revenue change (TTM)

21.46%

Earnings per share change (TTM)

45.94%

3-year revenue growth (CAGR)

-1.99%

3-year earnings per share growth (CAGR)

-31.52%

What the Analysts think about Innoviva

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Innoviva stock.

Innoviva Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Innoviva Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Innoviva News

AllArticlesVideos

Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States

GlobeNewsWire·4 weeks ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $INVA

$

Capital at risk

Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Innoviva stock?

Innoviva (INVA) has a market cap of $1.1B as of January 15, 2025.

What is the P/E ratio for Innoviva stock?

The price to earnings (P/E) ratio for Innoviva (INVA) stock is 17.93 as of January 15, 2025.

Does Innoviva stock pay dividends?

No, Innoviva (INVA) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Innoviva dividend payment date?

Innoviva (INVA) stock does not pay dividends to its shareholders.

What is the beta indicator for Innoviva?

Innoviva (INVA) has a beta rating of 0.57. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.